A Japanese study found high remission and continuation rates, plus non-inferior trough levels, after patients with IBD were switched to the infliximab biosimilar CT-P13.
Sandoz's Edward Li explains how biosimilar denosumab pricing could reshape cost-effectiveness, payer access, and gaps in ...
Patients with neovascular age-related macular degeneration (nAMD) who transitioned from off-label bevacizumab to a biosimilar and then to a branded anti-VEGF agent had longer injection intervals ...
Most pediatric and young adult patients with IBD maintained stable disease activity and laboratory markers after switching ...
A study found no direct trial evidence for natalizumab or its biosimilar in MS and found limited cost-effectiveness vs most ...
Analytical characterization supports monoclonal antibody biosimilar approvals and may reduce clinical testing needs, researchers found. As biosimilar development continues to expand across biologic ...
Rituximab biosimilars showed no significant 6-month differences vs the originator in antineutrophil cytoplasmic antibody–associated vasculitis (AAV). A 6-month, real-world comparison of rituximab ...
An editorial modeled on Hatch-Waxman proposes an abbreviated FDA pathway granting biosimilars class-level interchangeability to spur competition. An abbreviated biologics license application (ABLA) ...
Saudi real-world study finds adalimumab biosimilar switching preserves efficacy and safety, with full response in patients with HS. Adalimumab biosimilars maintained favorable efficacy and safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results